Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review compares mesotherapy and PRP for hair loss but reports no new clinical results; the authors highlight the need to understand their differences for optimal treatment choices.

Mesotherapy shows promise for cellulite and facial rejuvenation but has mixed results for body sculpting and hair loss, with more research needed for safety and effectiveness.

In this summary of needle mesotherapy's role in treating alopecia, the researchers highlight its use in delivering beneficial substances directly to the skin or hair follicles, showing hair loss reduction after one treatment and hair regrowth after several sessions, although contraindications exist for certain populations.

In this review, the authors assessed the efficacy of mesotherapy for alopecia treatment, finding that combining mesotherapy with minoxidil, PRP, or growth factors significantly improves hair density and thickness but noted the need for standardized protocols and larger studies to confirm long-term effectiveness.

Using truncal anesthesia on the supraorbital nerve reduces pain in hair loss treatments and improves patient comfort.

This review found that mesotherapy could improve hair density and reduce hair fall in androgenetic alopecia, especially when combined with other treatments, but lacks standardized protocols and long-term safety data.

This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that combining platelet-rich plasma with systemic therapies for androgenetic alopecia may result in greater improvements in hair density and width than using PRP alone, though the differences were not statistically significant.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.

This review synthesizes recent advancements in clinical trichology, highlighting updates on androgenetic alopecia treatments like low-dose oral minoxidil, 5α-reductase inhibitors, and other therapeutic options for various alopecia types, including telogen/anagen effluvium and alopecia areata, and detailed approaches for scarring alopecias and pediatric trichology.

This paper describes androgenic alopecia as a hereditary form of hair loss influenced by androgens, outlining its diagnosis, treatment options like minoxidil and finasteride, and the importance of psychological support due to its impact on quality of life.

This review of female androgenetic alopecia treatments reports limited therapeutic options due to unclear pathogenesis, with minoxidil as the only FDA-approved treatment and adjuvant therapies under investigation.

This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.

This review discusses novel treatments for androgenetic alopecia, including therapies like platelet-rich plasma and adipose-derived stem cells, and reports no new clinical results.

Stem cell treatment improved hair density in female hair loss patient.

This study reviewed evidence for six minimally invasive treatments for androgenetic alopecia, finding consistent support for platelet-rich plasma and topical finasteride, while other options like microneedling and intradermal dutasteride showed promise but need further and standardized research.

This study found that androgenetic alopecia patients treated with a combination of PRP and systemic therapy experienced greater but non-significant improvements in hair density and width compared to PRP monotherapy, without additional adverse effects, suggesting potential benefits for further exploration of combination regimens.

In this study, PRP combined with systemic therapy for androgenetic alopecia showed higher, but not statistically significant, improvements in hair density and width compared to PRP alone, with no increase in side effects; further prospective studies are recommended.

Microneedling combined with other treatments significantly improves hair growth in people with hair loss and is safe.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

In this series, patients experienced alopecia with limited regrowth following mesotherapy, indicating possible lasting aesthetic consequences and suggesting the need for careful technique and close follow-up, as the condition might be underrecognized.

In this retrospective analysis, dutasteride mesotherapy was used in 10 patients with androgenetic alopecia and resulted in hair density and width changes measured at the scalp, but specific efficacy results are not detailed in the abstract.

Mesotherapy and platelet-rich plasma treatments may help with hair loss, but their safety and effectiveness are still uncertain.

In this study, researchers found that adding zygomaticotemporal nerve blocks to supratrochlear and supraorbital nerve blocks in mesotherapy lowered pain significantly during and after the procedure for hair regrowth in alopecia patients.

This article reviews the classifications and characteristics of androgenic alopecia and provides no new clinical results; it emphasizes the importance for aestheticians to understand current treatment evidence.